Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5780)
  3. Review (420)
  4. Editorial (194)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13274)
  2. Center for Hematologic Malignancies (10609)
  3. GSK Faculty (4481)
  4. Adult Leukemia (3672)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2704)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (336)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (329)
  5. Haematologica (291)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1529)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13375)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Primary results of the phase 2 VALENTINE-PTCL01 study
    Meeting Abstract

    Horwitz, S. M.; Izutsu, K.; Mehta-Shah, N.; Cordoba, R.; Barta, S. K.; Bachy, E.; Gritti, G.; Jacobsen, E.; Kusumoto, S.; Guillermin, Y.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment effectiveness with venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: An international real-world study
    Meeting Abstract

    Ghosh, N.; Lamanna, N.; Eyre, T. A.; Coombs, C. C.; Manzoor, B. S.; Brown, J. R.; Tuncer, H. H.; Ujjani, C. S.; Leslie, L. A.; Roeker, L. E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy
    Meeting Abstract

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-b-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US intergroup double-blind randomized phase III study alliance A051301/BMT-CTN 1201
    Meeting Abstract

    Andreadis, C.; Bobek, O.; Hsi, E. D.; Fenske, T. S.; Geyer, S. M.; Stiff, P. J.; Hill, B. T.; Horwitz, M.; Khimani, F.; Little, R. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter, real-world study in patients with R/R large B- cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US)
    Meeting Abstract

    Crombie, J. L.; Nastoupil, L. J.; Andreadis, C.; Isufi, I.; Hunter, B.; Winter, A.; Hess, B.; Barta, S. K.; Frigault, M. J.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study
    Meeting Abstract

    Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume
    Meeting Abstract

    Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes of BMT CTN 1703: A randomized phase III study for GVHD prophylaxis - A quality of life evaluation
    Meeting Abstract

    Holtan, S. G.; Martens, M. J.; Al Malki, M. M.; Efebera, Y.; Kitko, C. L.; Reshef, R.; Rezvani, A. R.; Shaffer, B. C.; Solh, M. M.; Yao, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • (131)I-apamistamab effectively achieved durable responses in patients with R/R AML irrespective of the presence of multiple high-risk factors
    Meeting Abstract

    Seropian, S.; Foran, J. M.; Gyurkocza, B.; Nath, R.; Choe, H.; Litzow, M. R.; Koshy, N.; Stiff, P. J.; Tomlinson, B. K.; Abhyankar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: Results of the BMT CTN 1801 study
    Meeting Abstract

    Kean, L.; Siegel, S. J.; Schmalz, J. T.; Bien, S. A.; Scheffey, D.; Sanders, C.; Robins, H.; Applegate, K.; Bar, M.; Chhabra, S.; more...
    Blood (2023)

    Fulltext@MSK | Save